Adjuvants for allergy vaccines.

Area of Science:

• Immunology
• Allergy Research
• Vaccine Development

Background:

• Current allergen-specific immunotherapy (SCIT/SLIT) for Type I allergies lacks optimal adjuvants.
• Subcutaneous vaccines use aluminum hydroxide/calcium phosphate; sublingual vaccines use high-dose aqueous extracts without adjuvants.
• There's a need for adjuvants that promote Th1 and CD4+ regulatory T cell responses.

Purpose of the Study:

• To explore novel immunomodulators and delivery systems for enhanced allergen-specific immunotherapy.
• To identify adjuvants that can induce IL10, IL12, and IFNγ production.
• To investigate vector systems for improved allergen uptake by tolerogenic antigen-presenting cells.

Main Methods:

• Investigating immunomodulators like vitamin D3, probiotics (Lactobacillus, Bifidobacterium), and TLR ligands (TLR2, TLR4, TLR9).
• Exploring vector systems including mucoadhesive particles, virus-like particles, and liposomes.
• Preclinical allergy models are used to assess the efficacy of candidate adjuvants.

Main Results:

• Candidate adjuvants include glucocorticoids, vitamin D3, probiotics, and TLR agonists.
• Vector systems are being considered to facilitate allergen uptake by mucosal antigen-presenting cells.
• The focus is on inducing Th1 and regulatory T cell responses.

Conclusions:

• Novel adjuvants and delivery systems are crucial for advancing allergen-specific immunotherapy.
• Targeting dendritic and T cell functions can enhance therapeutic immune responses.
• Future strategies involve combining immunomodulators with advanced vector systems for improved allergy treatment.